Clene Inc. (CLNN)
Clene Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Its lead candidate, CNM-Au8, has been evaluated in multiple clinical studies across neurological conditions, including amyotrophic lateral sclerosis, early symptomatic ALS, chronic optic neuropathy linked to visual pathway deficits, stable relapsing multiple sclerosis, and Parkinson’s disease. The company is also developing CNM-AgZn17 for infectious diseases and wound healing support, as well as CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent intended to address infection and immune support. In addition, Clene markets dietary supplements such as rMetx and KHC46. Clene Inc. is headquartered in Salt Lake City, Utah, and its common stock trades on NASDAQ under the symbol CLNN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CLNN
|
$5.57
|
-3.1% Downside
|
Fair
|
$32.20
|
460.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-2.2x
|
-3.9x
|
549.3x
|
73.22 M
|
89.712 M
|
23.1%
|
82.2%
|
-22.2
|
—
|
54.0%
|
